证券代码：300434 证券简称：金石亚药 公告编号：2024-023 关于全资子公司获得磷酸奥司他韦胶囊药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，四川金石亚洲医药股份有限公司（以下简称"公司"）之全资子公司 海南亚洲制药股份有限公司（以下简称"亚洲制药"）收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的《药品注册证书》。现就相关情况公告 如下： 一、药品基本情况 药品名称：磷酸奥司他韦胶囊 剂型：胶囊剂 四川金石亚洲医药股份有限公司 规格：75mg（按 C16H28N2O4计） 注册分类：化学药品 4 类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 二、药品其他相关情况 本品主要成分为磷酸奥司他韦，适应症为：1、用于成人和 1 岁及 1 岁以上 儿童的甲型和乙型流感治疗（磷酸奥司他韦能够有效治疗甲型和乙型流感，但是 乙型流感的临床应用 ...

Financial Performance - The company's revenue for Q3 2024 reached ¥234,715,731.62, representing a 21.40% increase compared to the same period last year[2] - Net profit attributable to shareholders was ¥18,926,849.28, a significant increase of 211.68% year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥15,005,022.22, up 184.20% from the previous year[2] - Total operating revenue for Q3 2024 was CNY 756,645,811.15, a decrease of 8.5% compared to CNY 827,063,956.04 in Q3 2023[13] - The net profit for Q3 2024 was CNY 55,880,555.94, a decrease of 58.8% compared to CNY 135,495,906.37 in Q3 2023[14] - Operating profit for the quarter was CNY 89,032,917.43, a decline of 48.0% from CNY 171,625,782.06 in the same period last year[14] - The total profit for the quarter was CNY 82,697,515.64, a decrease of 51.9% from CNY 171,830,475.49 in the same quarter last year[14] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥2,834,722,341.46, down 8.60% from the end of the previous year[2] - The company's total assets decreased to CNY 2,834,722,341.46 from CNY 3,101,438,665.01, a decline of about 8.6%[12] - Current liabilities totaled CNY 328,672,372.05, down significantly from CNY 601,171,878.83, indicating a reduction of approximately 45%[12] - Non-current liabilities decreased to CNY 69,195,210.57 from CNY 76,200,757.36, a decline of about 9.3%[12] - The company's total equity increased to CNY 2,436,854,758.84 from CNY 2,424,066,028.82, reflecting a growth of approximately 0.5%[12] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥71,394,399.48, a decrease of 10.65% compared to the same period last year[5] - The net cash flow from operating activities was 71,394,399.48, a decrease from 79,904,989.91 in the previous period, indicating a decline of approximately 6.3%[17] - The total cash outflow from investing activities was 244,194,515.72, significantly higher than 33,873,973.94 in the previous period, reflecting an increase of over 620%[17] - The net cash flow from financing activities was -49,979,024.03, compared to -470,812.35 in the previous period, showing a substantial increase in cash outflow[17] - The total cash and cash equivalents at the end of the period were 357,383,549.09, down from 511,952,047.47, representing a decrease of approximately 30%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,678[7] - The largest shareholder, Gao Yaping, holds 25.11% of the shares, totaling 100,878,929 shares[7] - The company has a significant number of shares held by major shareholders, with the top three shareholders holding a combined total of 93.34%[7] - The company reported a total of 66,961,406 restricted shares at the beginning of the period, with 7,338,620 shares released during the period, leaving 59,622,786 restricted shares at the end[9] Operational Highlights - The company is focusing on expanding its production facilities, as indicated by a significant increase of 10,881.85% in construction in progress[5] - The company plans to continue its market expansion and product development strategies in the upcoming quarters[9] Revenue and Expenses - Total operating costs increased to CNY 670,119,991.15, up from CNY 651,362,855.09, reflecting a rise of approximately 2.5%[13] - Sales expenses increased to CNY 172,290,852.34, up 9.0% from CNY 156,857,766.57 in Q3 2023[14] - Research and development expenses decreased to CNY 30,034,741.20, down 25% from CNY 40,018,123.05 in the previous year[14] Investment and Receivables - The company’s trading financial assets increased significantly from 42,358,661.00 CNY to 174,087,628.76 CNY during the reporting period[10] - Accounts receivable rose from 79,477,350.02 CNY to 97,124,214.67 CNY, indicating a growth of approximately 22.5%[10] - The company’s financing receivables decreased from 296,290,232.19 CNY to 131,272,536.64 CNY, a decline of about 55.7%[10] - Other receivables decreased from 24,473,816.03 CNY to 21,245,512.18 CNY, a reduction of approximately 13.3%[10]

证券代码：300434 证券简称：金石亚药 公告编号：2024-021 四川金石亚洲医药股份有限公司 1、审议通过《2024 年第三季度报告》 经审核，监事会认为：公司董事会编制和审核公司《2024 年第三季度报告》 的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地 反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《2024 年第三季度报告》详见公司同日在巨潮资讯网及公司指定信息披露 媒体发布的相关公告。 表决结果：3 票同意，0 票反对，0 票弃权，本议案获得通过。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第五届监事会第五次 会议于 2024 年 10 月 22 日上午以通讯表决方式召开，会议通知已于 2024 年 10 月 12 日以电子邮件或网络方式发出。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席汪进先生主持。本次会议的召集、召开符合《公司 法》及《公司章程》的有关规定，会议表决合法有效。 二、监事会会 ...

证券代码：300434 证券简称：金石亚药 公告编号：2024-020 四川金石亚洲医药股份有限公司（以下简称"公司"）第五届董事会第五次 会议于 2024 年 10 月 22 日在浙江杭州亚科中心公司会议室以现场结合通讯表决 方式召开。本次董事会会议通知已于 2024 年 10 月 12 日以电子邮件或网络方式 发出。会议应出席董事 11 名，实际出席董事 11 名；其中，董事郑志勇先生、盛 晓霞女士，独立董事钟鹏先生、赵小微女士以通讯表决方式出席本次会议。本次 会议由董事长马益平先生主持。公司全体监事、高级管理人员列席了本次会议。 本次会议的召集、召开程序符合《公司法》及《公司章程》的有关规定，会议表 决合法有效。 二、董事会会议审议情况 经研究讨论，会议达成如下决议： 1、审议通过《2024 年第三季度报告》 《2024 年第三季度报告》详见公司同日在巨潮资讯网及公司指定信息披露 媒体发布的相关公告。 四川金石亚洲医药股份有限公司 第五届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 公司监事会对公司《2 ...

证券代码：300434 证券简称：金石亚药 公告编号：2024-019 四川金石亚洲医药股份有限公司 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" （https://rs.p5w.net）参与本次互动交流，活动时间为 2024 年 9 月 12 日（周四） 13:00-17:00。 届时，公司董事长/总经理马益平先生、董事/副总经理/董事会秘书林强先生、 财务总监王庆国先生将在线就公司 2023 年度及 2024 年半年度业绩、公司治理、 发展战略、 经营状况、融资计划、股权激励和可持续发展等投资者关心的问题， 与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 四川金石亚洲医药股份有限公司 董 事 会 二〇二四年九月九日 关于参加四川辖区 2024 年投资者网上集体接待日活动及 半年度报告业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，四川金石亚洲医药股份有限公司（以下 简称"公司"）将参加由四川省上市公司协会、上证所信息网络有限公司、深圳 市全景网络有限公司联合举办的"四川辖区 20 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥521,930,079.53, a decrease of 17.64% compared to ¥633,725,687.05 in the same period last year[15]. - The net profit attributable to shareholders for the first half of 2024 was ¥39,202,246.68, down 74.83% from ¥155,730,458.83 in the previous year[15]. - The net cash flow from operating activities was negative at ¥89,021,457.33, a decline of 187.92% compared to a positive cash flow of ¥101,258,528.41 in the same period last year[15]. - Basic earnings per share decreased to ¥0.0976, down 74.82% from ¥0.3876 in the previous year[15]. - Total assets at the end of the reporting period were ¥2,809,375,783.63, a decrease of 9.42% from ¥3,101,438,665.01 at the end of the previous year[15]. - The net assets attributable to shareholders were ¥2,395,439,946.23, a slight decrease of 0.21% from ¥2,400,429,525.47 at the end of the previous year[15]. - The weighted average return on net assets was 1.62%, down 5.00% from 6.62% in the previous year[15]. - The company reported a non-recurring loss of ¥56,447.43 from the disposal of non-current assets[17]. - The fair value changes and disposal gains from financial assets and liabilities resulted in a profit of ¥679,867.08[17]. - The company's total liabilities amounted to CNY 56,226,936.71, significantly higher than CNY 20,930,401.48 in the previous year[118]. Market Position and Strategy - The company has over 90 drug production approval numbers and 7 health food production approval numbers, with a significant portion of revenue coming from the "Kuaike" cold medicine series, which includes products like compound acetaminophen and pediatric acetaminophen granules[3]. - The company is focused on maintaining its competitive advantage in the cold medicine market, but potential advancements in treatment solutions could pose a threat to its market position[3]. - The OTC market for cold medicine in China is projected to grow significantly, with a market size expected to increase from ¥397.42 billion in 2024 to ¥509.89 billion by 2030[19]. - The health food market in China is forecasted to grow from ¥211.3 billion in 2022 to ¥286.7 billion by 2027, with a compound annual growth rate of 6.3%[20]. - The company ranked among the top 100 chemical pharmaceutical companies in China for 2023, indicating strong market positioning[21]. - The company is the creator and owner of the leading cold medicine brands "Kuaike" and "Xiaokuaike," which have consistently ranked high in OTC product statistics[21]. - The company is focused on integrating drug research, production, and sales to enhance its competitive edge in the pharmaceutical health sector[21]. - The company plans to expand its market presence through new product launches and technological advancements in the pharmaceutical sector[15]. Investment and Development - The company plans to invest in projects such as the Zhejiang Yafeng Pharmaceutical production base and the subsidiary formulation workshop renovation, which involve substantial investment amounts[4]. - The company is developing a pipeline that includes integrated raw material drug formulations and calcium mineral series products, but drug development and approval processes are lengthy and subject to uncertainties[3]. - The company is focusing on the development of new composite pipeline technologies and manufacturing equipment as part of its strategic initiatives[15]. - The company is focusing on the development of prescription drugs, particularly in the anti-inflammatory and analgesic categories, to extend its product line[23]. - The company has achieved steady sales growth for "Kuaike Lin" after winning provincial-level collective procurement bids[22]. Risks and Challenges - The company faces risks from intensified domestic market competition and potential impacts from changes in health and pharmaceutical policies, including reduced import tariffs and increased competition from foreign pharmaceutical companies[1]. - The average profit margin in the pharmaceutical industry may decline due to government price control policies, which could adversely affect the company's operating performance[4]. - The company acknowledges the risk of proprietary technology loss or leakage, despite having established confidentiality agreements and a robust technical retention system[4]. - The company has established long-term stable business cooperation with major suppliers, ensuring a steady supply of raw materials, but remains vulnerable to potential shortages and price increases due to unforeseen circumstances[2]. Environmental and Social Responsibility - The company is committed to sustainable and environmentally friendly practices in its vacuum coating equipment development, focusing on energy-saving and new energy solutions[25]. - The company has established an online monitoring system for wastewater discharge, ensuring compliance with environmental regulations[58]. - The company has actively engaged in social responsibility initiatives, including donations to various charitable organizations totaling over 100,000 yuan during the reporting period[66]. - The company reported a donation of 74,328 yuan in educational materials to two primary schools in May 2024[67]. - The company has adhered to environmental protection regulations and has not experienced any pollution incidents during the reporting period[66]. Financial Management and Reporting - The company does not plan to distribute cash dividends, issue bonus shares, or convert reserves into share capital[5]. - The company has not reported any significant changes in its registration or contact information during the reporting period[12]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[51]. - The company has not made any significant acquisitions or mergers during the reporting period[70]. - The financial report for the half-year period has not been audited[110]. - The company has not issued any non-standard audit reports for the half-year financial report[68]. Research and Development - The company emphasizes product quality control, adhering to internal standards that exceed national requirements, and has not faced significant product quality disputes during the reporting period[4]. - Research and development expenses decreased by 28.71% to ¥19,863,344.15 from ¥27,863,062.95 year-on-year[29]. - The company has a robust research and development strategy, combining independent and collaborative efforts, with a focus on enhancing its product pipeline and project management[26].

四川金石亚洲医药股份有限公司 第五届监事会第四次会议决议公告 证券代码：300434 证券简称：金石亚药 公告编号：2024-016 二、监事会会议审议情况 经研究讨论，会议达成如下决议： 1、审议通过《2024 年半年度报告全文及摘要》 经审核，监事会认为：公司董事会编制和审核公司《2024 年半年度报告全 文及摘要》的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者 重大遗漏。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第五届监事会第四次 会议于 2024 年 8 月 27 日上午以通讯表决方式召开，会议通知已于 2024 年 8 月 23 日以电子邮件或网络方式发出。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席汪进先生主持。本次会议的召集、召开符合《公司法》 及《公司章程》的有关规定，会议表决合法有效。 三、备查文件 1、《第五届监事会第四次会议决议》。 特此公告。 四川 ...

证券代码：300434 证券简称：金石亚药 公告编号：2024-015 四川金石亚洲医药股份有限公司 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 经研究讨论，会议达成如下决议： 1、审议通过《2024 年半年度报告全文及摘要》 《2024 年半年度报告》详见公司同日在巨潮资讯网发布的相关公告，《2024 年半年度报告摘要》详见公司同日在巨潮资讯网及公司指定信息披露媒体发布的 相关公告。 公司监事会对公司《2024 年半年度报告全文及摘要》进行审核并发表了审 核意见，具体意见内容详见公司同日在巨潮资讯网发布的相关公告。公司董事会 审计委员会召开会议，对公司《2024 年半年度报告全文及摘要》进行审核并发 表了审核意见。 表决结果：11 票同意，0 票反对，0 票弃权，本议案获得通过。 三、备查文件 1、《第五届董事会第四次会议决议》； 2、《第五届董事会审计委员会 2024 年第四次会议纪要》； 四川金石亚洲医药股份有限公司（以下简称"公司"）第五届董事会第四次 会议于 2024 ...

四川金石亚洲医药股份有限公司2024半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人： 马益平 主管会计工作负责人： 王庆国 会计机构负责人： 王庆国 本表已于2024年8月27日获董事会批准 | 编制单位：四川金石亚洲医药股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公司 | 上市公司核算的 | 2024年期初占用 | 2024年半年度占 | 2024年半年度 | 2024年半年度偿 | 2024年半年度期 | | | | 非经营性资金占用 | 资金占用方名称 | 的关联关系 | 会计科目 | 资金余额 | 用累计发生金额 （不含利息） | 占用资金的利息 （如有） | 还累计发生金额 | 末占用资金余额 | 占用形成原因 | 占用性质 | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制人及其附属企 ...

四川金石亚洲医药股份有限公司 2023 年度独立董事述职报告 （钟鹏） 本人钟鹏，自 2023 年 12 月 22 日经四川金石亚洲医药股份有限公司（以下 简称"公司"）2023 年第一次临时股东大会选举为公司独立董事。作为公司独 立董事，本人严格按照《公司法》、《上市公司独立董事管理办法》、《深圳证 券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》以及《公司章程》、《公司独立董事工作制度》 等法律、法规、部门规章和规范性文件及公司规章制度的有关规定，独立、勤勉 地履行职责，有效发挥独立董事的作用。现将 2023 年度工作情况述职如下： 一、独立董事的基本情况 (一)个人基本情况及工作履历 钟鹏，男，中国国籍，1975 年出生，研究生学历，法学硕士，执业律师。 曾就职于上海市经建律师事务所；2004 年至 2015 年任上海市和华利盛律师事务 所合伙人；2015 年至 2017 年任德恒上海律师事务所高级合伙人。2017 年至今担 任北京市竞天公诚律师事务所高级合伙人，2023 年 12 月至今担任四川金石亚洲 医药股份有限公司独立董事。 (二)关于独立性 ...